(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 16.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Genmab A's revenue in 2025 is $3,148,620,000.On average, 7 Wall Street analysts forecast GMAB's revenue for 2025 to be $235,562,958,971, with the lowest GMAB revenue forecast at $230,761,606,667, and the highest GMAB revenue forecast at $245,424,958,185. On average, 7 Wall Street analysts forecast GMAB's revenue for 2026 to be $284,229,848,815, with the lowest GMAB revenue forecast at $266,973,485,052, and the highest GMAB revenue forecast at $304,692,674,683.
In 2027, GMAB is forecast to generate $331,848,108,117 in revenue, with the lowest revenue forecast at $305,963,661,768 and the highest revenue forecast at $351,034,055,345.